- Home
- TPST vs COCP Comparison
TPST vs COCP Comparison
Compare TPST & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | COCP |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 14.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | COCP |
|---|---|---|
| Price | $2.92 | $1.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $12.50 | $6.00 |
| AVG Volume (30 Days) | ★ 242.3K | 58.8K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.00 | $0.90 |
| 52 Week High | $13.65 | $3.26 |
Technical Indicators
Market Signals| Indicator | TPST | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 24.61 | 47.54 |
| Support Level | $3.04 | $1.01 |
| Resistance Level | $3.23 | $1.10 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 3.18 | 59.86 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).